EUCTR2020-002470-27-SE进行中（未招募）1 期
A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODIC MIGRAINE
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 670
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent and participant privacy information (eg, written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures;
- •2. Participants must be using a medically acceptable and effective method of birth control during the course of the entire study, as defined in Section 4.5.2 of the protocol;
- •3. Eligible participants who completed the double-blind treatment period (Visit 7) and the follow-up period (Visit 8), if applicable, depending on the timing of study initiation, of Study 3101-303-002 or Study 3101-304-002 without significant protocol deviations (eg, noncompliance to protocol-required procedures) and who did not experience an AE that, in the investigator’s opinion, may indicate an unacceptable safety risk.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 647
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 23
排除标准
- •1. Requirement for any medication, diet (ie, grapefruit or grapefruit juice), or
- •nonpharmacological treatment that is on the list of prohibited concomitant medications or treatments that cannot be discontinued or switched to an allowable alternative medication or treatment.
- •Exception: participants from lead-in Study 3101-303-002 taking only 1 migraine
- •prevention medication at a stable, well-tolerated dose during the lead-in study; the medication may be continued at the same dose or discontinued;
- •2. Female participant is pregnant, planning to become pregnant during the course of the study, or currently lactating. WOCBP must have a negative urine pregnancy test at Visit 1;
- •3. An ECG with clinically significant abnormalities at Visit 1 as determined by the
- •investigator;
- •4. Hypertension as defined by sitting systolic BP > 160 mm Hg or sitting diastolic
- •BP > 100 mm Hg at Visit 1. Vital sign measurements that exceed these limits may be repeated only once;
- •5. Significant risk of self-harm based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigator; participants must be excluded if they report suicidal ideation with intent, with or without a plan (ie, Type 4 or 5 on the C-SSRS) since the last visit;
- •6. Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease;
- •7. Participant has a condition or is in a situation which in the investigator's opinion may put the participant at significant risk, may confound the study results, or may interfere significantly with participation in the study;
- •8. Any medical or other reasons (eg, unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study) that, in the investigator’s opinion, might indicate that the participant is unsuitable for participation in the study.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineChronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10066636Term: Chronic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 22.0Level: LLTClassification code 10082019Term: Episodic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-002470-27-FRAllergan Limited670
进行中（未招募）
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineEUCTR2020-002470-27-ITALLERGAN LIMITED670
招募中
3 期
A study evaluating oral Atogepant for the Prevention of Migraine in Japanese Participants with Chronic or Episodic MigraineJPRN-jRCT2080225228Allergan, Inc140
进行中（未招募）
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineEUCTR2020-002470-27-CZAbbVie Deutschland GmbH & Co. KG670
进行中（未招募）
1 期
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraineCronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)MedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10066636Term: Chronic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 22.0Level: LLTClassification code 10082019Term: Episodic migraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-002470-27-HUAbbVie Deutschland GmbH & Co. KG670